Delivery Order SPE2DB22D9367-SPE2DB25FSW02

Award Date 1/7/25
Potential Completion Date 1/29/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $5,136.69 delivery order is for the supply of 4567630694 - XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm fixed-price delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $17,122.30 award is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product, to support the recurring medical supply needs of military health facilities worldwide. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $13,697.84 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML medical supplies. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $35,132.68 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product, to support the recurring medical supply needs of military healthcare facilities. The contract is not associated with a specific set-aside designation, which allows DMS...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $51,366.90 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with an ultimate completion date of October 21, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,410.07 contract is for the provision of Xolair 300 mg/2 ml autoinjector 2 ml, a specialized pharmaceutical product. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,712.22 contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialized pharmaceutical product, with a period of performance through January 9, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $35,956.83 contract is for the delivery of Xolair 300 mg/2 ml autoinjectors to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $15,245.24 contract is for the supply of 4566873659 ! XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product, with a period of performance through January 29, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,273.38 contract is for the delivery of Xolair 300 mg/2 ml autoinjector medication to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
  • SPE2DB22D9367
    Indefinite Delivery Contract
  • SPE2DB22D9367-SPE2DB25FSW02
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $10,273.38 contract is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a specialized pharmaceutical product. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains. This contract award demonstrates DMS Pharmaceutical Group's capability to provide specialized medications and medical supplies to the Department of Defense (DoD) healthcare system.

Generated 4/8/25, 10:00 AM